Arrowhead Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Arrowhead Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 33.4% e 39.5% all'anno. Si prevede che l'EPS crescerà di 36.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -2283.7% in 3 anni.

Informazioni chiave

33.4%

Tasso di crescita degli utili

36.1%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	27.6%
Tasso di crescita dei ricavi	39.5%
Rendimento futuro del capitale proprio	-2,283.7%
Copertura analitica	Good
Ultimo aggiornamento	20 Dec 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Apr 03

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Mar 30

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Jan 21

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Dec 25

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Sep 19

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Mar 10

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:ARWR - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
9/30/2027	351	-302	-348	-154	9
9/30/2026	195	-468	-389	-311	12
9/30/2025	276	-309	268	285	16
9/30/2024	4	-599	-604	-463	N/A
6/30/2024	20	-539	-533	-352	N/A
3/31/2024	35	-471	-470	-257	N/A
12/31/2023	182	-297	-403	-196	N/A
9/30/2023	241	-205	-331	-154	N/A
6/30/2023	256	-181	-342	-197	N/A
3/31/2023	273	-150	-353	-245	N/A
12/31/2022	278	-155	-236	-150	N/A
9/30/2022	243	-176	-189	-136	N/A
6/30/2022	250	-154	-120	-91	N/A
3/31/2022	263	-112	-75	-52	N/A
12/31/2021	144	-183	124	149	N/A
9/30/2021	138	-141	148	171	N/A
6/30/2021	108	-126	167	184	N/A
3/31/2021	89	-110	165	181	N/A
12/31/2020	80	-103	-123	-111	N/A
9/30/2020	88	-85	-108	-96	N/A
6/30/2020	124	-24	-89	-71	N/A
3/31/2020	139	10	-46	-27	N/A
12/31/2019	164	53	-34	-19	N/A
9/30/2019	169	68	161	173	N/A
6/30/2019	137	46	152	157	N/A
3/31/2019	95	10	130	132	N/A
12/31/2018	47	-29	134	136	N/A
9/30/2018	16	-54	-49	-47	N/A
6/30/2018	14	-54	N/A	-54	N/A
3/31/2018	22	-44	N/A	-50	N/A
12/31/2017	31	-35	N/A	-49	N/A
9/30/2017	31	-34	N/A	-24	N/A
6/30/2017	23	-46	N/A	-25	N/A
3/31/2017	13	-60	N/A	-33	N/A
12/31/2016	4	-75	N/A	-33	N/A
9/30/2016	0	-82	N/A	-64	N/A
6/30/2016	0	-84	N/A	-66	N/A
3/31/2016	0	-81	N/A	-61	N/A
12/31/2015	0	-89	N/A	-63	N/A
9/30/2015	0	-92	N/A	-66	N/A
6/30/2015	0	-90	N/A	-65	N/A
3/31/2015	0	-85	N/A	-61	N/A
12/31/2014	0	-71	N/A	-53	N/A
9/30/2014	0	-59	N/A	-35	N/A
6/30/2014	0	-50	N/A	-30	N/A
3/31/2014	0	-44	N/A	-25	N/A
12/31/2013	0	-37	N/A	-22	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ARWR rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ARWR rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ARWR rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ARWR ( 39.5% all'anno) crescerà più rapidamente del mercato US ( 9.1% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ARWR ( 39.5% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che ARWR non sarà più redditizia tra 3 anni.

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/23 13:26
Prezzo dell'azione a fine giornata	2024/12/23 00:00
Guadagni	2024/09/30
Guadagni annuali	2024/09/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Arrowhead Pharmaceuticals, Inc. è coperta da 29 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Ishan Majumdar	Baptista Research
Ying Huang	Barclays
Jason Matthew Gerberry	BofA Global Research

Arrowhead Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates increase by 12%

Consensus revenue estimates increase by 66%

Consensus revenue estimates decrease by 14%

Consensus revenue estimates fall by 22%

Price target decreased by 7.5% to US$46.54

Consensus revenue estimates decrease by 19%, EPS upgraded

Recent updates

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

CEO, President & Director recently sold US$567k worth of stock

CEO, President & Director notifies of intention to sell stock

Consensus revenue estimates increase by 12%

Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Consensus revenue estimates increase by 66%

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity

New minor risk - Revenue size

Full year 2024 earnings: EPS and revenues miss analyst expectations

Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors

Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

New major risk - Financial position

Consensus revenue estimates decrease by 14%

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Consensus revenue estimates fall by 22%

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

Price target decreased by 7.5% to US$46.54

New minor risk - Financial position

Third quarter 2024 earnings released: US$1.38 loss per share (vs US$0.96 loss in 3Q 2023)

Arrowhead Pharmaceutical: Driving To Commercialization

Now 20% overvalued after recent price rise

Now 8.9% undervalued

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Now 26% overvalued

Now 21% overvalued

Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals: Hoping Something Sticks

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023)

Now 24% undervalued after recent price drop

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Chief Financial Officer recently sold US$1.4m worth of stock

Chief Financial Officer notifies of intention to sell stock

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Now 25% overvalued after recent price rise

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Consensus revenue estimates decrease by 19%, EPS upgraded

First quarter 2024 earnings: EPS and revenues miss analyst expectations

CEO, President & Director notifies of intention to sell stock

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Insider notifies of intention to sell stock

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.

CEO, President & Director notifies of intention to sell stock

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

CEO, President & Director notifies of intention to sell stock

Price target decreased by 7.7% to US$52.23

Consensus revenue estimates fall by 10%

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Financial position

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

New minor risk - Insider selling

Chief Medical Officer recently sold US$567k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

New major risk - Revenue and earnings growth

CEO, President & Director notifies of intention to sell stock

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Financial Officer recently sold US$543k worth of stock